Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | KDM5A | P29375 | 4/20 | 0.42 |
| ▸ | PHF8 | Q9UPP1 | 2/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP3 | P08254 | 1/20 | 0.38 |
| ▸ | MMP8 | P22894 | 1/20 | 0.38 |
| ▸ | THRA | P10827 | 2/20 | 0.37 |
| ▸ | THRB | P10828 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formic Acid SCHEMBL9721362 | 0.97 | CA12 (0.44) | CA12CA1CA9KDM5APHF8 | |
| Formic Acid SCHEMBL1131732 | 0.91 | CA12 (0.40) | CA12CA1CA9KDM5APHF8 | |
| Formic Acid SCHEMBL2867086 | 0.90 | DNM1 (0.46) | CA12CA1CA9KDM5APHF8 | |
| Formic Acid SCHEMBL28121779 | 0.90 | DNM1 (0.46) | CA12CA1CA9KDM5APHF8 | |
| Formic Acid SCHEMBL4355881 | 0.82 | CA12 (0.42) | CA12CA1CA9TSHRCYP3A4 | |
| Hydrogen Peroxide SCHEMBL137833 | 0.82 | KDM5A (0.48) | CA12CA1CA9KDM5APHF8 | |
| Methyl Alcohol SCHEMBL3078253 | 0.82 | CA12 (0.48) | CA12CA1CA9KDM5APHF8 | |
| Hydrogen Peroxide SCHEMBL137835 | 0.82 | KDM5A (0.48) | CA12CA1CA9KDM5APHF8 | |
| SCHEMBL3904839 | 0.82 | TSHR (0.46) | CA12CA1CA9KDM5APHF8 | |
| SCHEMBL27566038 | 0.82 | TSHR (0.46) | CA12CA1CA9KDM5APHF8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115340446-A | Chiral benzocyclobutene alcohol, and synthesis method and application thereof | 复旦大学 | 2022-11-15 | — | — | CN | claimed |
| EP-2821399-A1 | Method for preparation of 6-trifluoromethylpyridine-3-carboxylic acid derivatives from 4,4,4-trifluoro-3-oxobutanoyl chloride | Lonza Ltd (CH) | 2015-01-07 | — | — | EP | claimed |
| EP-2818461-A1 | Method for preparation of 6-trifluoromethylpyridine-3-carboxylic acid derivatives from 4,4,4-trifluoro-3-oxobutanoyl chloride | Lonza Ltd (CH) | 2014-12-31 | — | — | EP | claimed |
| US-20130096346-A1 | RESOLUTION METHODS FOR ISOLATING DESIRED ENANTIOMERS OF TAPENTADOL INTERMEDIATES AND USE THEREOF FOR THE PREPARATION OF TAPENTADOL | ACTAVIS GROUP PTC EHF (IS) | 2013-04-18 | — | — | US | claimed |
| EP-2542521-A2 | IMPROVED RESOLUTION METHODS FOR ISOLATING DESIRED ENANTIOMERS OF TAPENTADOL INTERMEDIATES AND USE THEREOF FOR THE PREPARATION OF TAPENTADOL | Actavis Group Ptc Ehf (IS) | 2013-01-09 | — | — | EP | claimed |
| US-20110318417-A1 | HIGHLY PURE CINACALCET OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ACTAVIS GROUP PTC EHF (IS) | 2011-12-29 | — | — | US | claimed |
| EP-2376424-A1 | HIGHLY PURE CINACALCET OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Actavis Group PTC EHF (IS) | 2011-10-19 | — | — | EP | claimed |
| WO-2011107876-A2 | IMPROVED RESOLUTION METHODS FOR ISOLATING DESIRED ENANTIOMERS OF TAPENTADOL INTERMEDIATES AND USE THEREOF FOR THE PREPARATION OF TAPENTADOL | ACTAVIS GROUP PTC EHF (IS) | 2011-09-09 | — | — | WO | claimed |
| WO-2010067204-A1 | HIGHLY PURE CINACALCET OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ACTAVIS GROUP PTC EHF (IS) | 2010-06-17 | — | — | WO | claimed |
| US-20250242275-A1 | APPARATUS AND METHOD FOR PROCESSING A BIOMASS MATERIAL | BUSS-SMS-CANZLER GMBH (DE) | 2025-07-31 | — | — | US | disclosed |
| US-20250145889-A1 | METHOD FOR PROCESSING A BIOMASS MATERIAL | PROIONIC GMBH (AT) | 2025-05-08 | — | — | US | disclosed |
| CN-118804981-A | Method for processing biomass material | 普罗奥尼克股份有限公司 | 2024-10-18 | — | — | CN | disclosed |
| EP-4377467-A2 | METHOD FOR PROCESSING A BIOMASS MATERIAL | proionic GmbH (AT) | 2024-06-05 | — | — | EP | disclosed |
| WO-2023084131-A2 | METHOD FOR PROCESSING A BIOMASS MATERIAL | PROIONIC GMBH (AT) | 2023-05-19 | — | — | WO | disclosed |
| CN-1249045-C | Process for preparing isoflavones | DSM IP ASSETS BV (NL) | 2006-04-05 | — | — | CN | disclosed |
| CN-1505621-A | Process for the preparation of isoflavones | DSM IP �ʲ�����˾ | 2004-06-16 | — | — | CN | disclosed |
| US-20030091838-A1 | Composition for film formation, method of film formation, and silica-based film | JSR CORPORATION (JP) | 2003-05-15 | — | — | US | disclosed |
| EP-0429995-B1 | Process for hydrogenation of oils | HELIOS OLJARNA DOMZALE D O O (YU) | 1996-02-28 | — | — | EP | disclosed |
| EP-0429995-A2 | Process for hydrogenation of oils | HELIOS OLJARNA DOMZALE d.o.o. (YU) | 1991-06-05 | — | — | EP | disclosed |
| US-4334117-A | DIMERIZATION OF BUTADIENE/1,3-/ AND ISOPRENE | KURARAY CO., LTD. (JP) | 1982-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110318417-A1 | HIGHLY PURE CINACALCET OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, REN, SLC6A12 | CA12 173/4885CA1 1068/4885CA9 25/4885 |
| US-20130096346-A1 | RESOLUTION METHODS FOR ISOLATING DESIRED ENANTIOMERS OF TAPENTADOL INTERMEDIATES AND USE THEREOF FOR THE PREPARATION OF TAPENTADOL | OPRD1, OPRK1, OPRM1 | CA12 2890/4885CA1 2183/4885CA9 1782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.